about
Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study.Distribution of high and low risk HPV types by cytological status: a population based study from Italy.Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study.Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix.Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients.[Molecular biomarkers and early diagnosis of lung cancer: state of knowledge and future perspectives].[HPV primary test in the cervical cancer screening: reproducibility assessment and investigation on cytological outcome of Hybrid Capture 2 borderline samples].Genetic analysis in nine unrelated Italian patients affected by OTC deficiency: detection of novel mutations in the OTC geneTriage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessmentAssociation of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsiesPrognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytologyMolecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis
P50
Q33636859-82A8BA92-BA28-49EA-9281-AA3EC4019220Q34573950-94C62354-5905-4713-8551-4707851086B1Q35066980-860731C9-626D-4C1E-8014-50C2EFCFB947Q35690377-B6789E11-B4AD-4373-994C-44B05C1F8330Q38733634-3D51CD1C-5B45-41A5-A9DE-69D7378C6C24Q39013857-E5BBB609-605F-4C72-B88C-3BA5F0E99C67Q41548112-BD177752-24CF-444B-8E1E-D537BE1DEF8DQ44119126-0DD1939C-3A13-496D-AD93-5C18BDFB2993Q51547564-60B506CF-8135-4C1C-9377-3CDFB4C20ACCQ52984493-18AE93ED-B65A-4C6B-8B7A-B41E2C272B6EQ53058781-5A840893-C0D2-44C4-8A1B-FC8DCA4BDD32Q74361154-56A9B16F-415A-4AC7-A4BF-245399186851Q81129212-0068273E-8C58-47B7-A0DB-99C6483D033BQ81262405-7461A022-5051-4554-863B-DD9512671FFCQ83152799-AAC60151-AD61-4ED7-A359-7D66C9D915DBQ84330504-BCF5A399-45D2-41BF-919E-FF001516D42F
P50
description
researcher ORCID ID = 0000-0001-8119-9119
@en
wetenschapper
@nl
name
Simonetta Bisanzi
@ast
Simonetta Bisanzi
@en
Simonetta Bisanzi
@es
Simonetta Bisanzi
@nl
type
label
Simonetta Bisanzi
@ast
Simonetta Bisanzi
@en
Simonetta Bisanzi
@es
Simonetta Bisanzi
@nl
prefLabel
Simonetta Bisanzi
@ast
Simonetta Bisanzi
@en
Simonetta Bisanzi
@es
Simonetta Bisanzi
@nl
P106
P31
P496
0000-0001-8119-9119